Jazz Pharmaceuticals vs Johnson & Johnson
Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $14.8B
- Last close
- $230.26
- 12 months
- +31.0%
- Market value
- $651B
- Last close
- $270.47
- 12 months
- +33.2%
At a glance
- The biggest part of Jazz Pharmaceuticals's revenue is Xywav (39%); at Johnson & Johnson it is Innovative Medicine (64%).
- Jazz Pharmaceuticals earns 90% of its revenue in the United States, Johnson & Johnson 57%.
- By market value, Johnson & Johnson ($651.1B) is about 44 times Jazz Pharmaceuticals ($14.8B).
- Over the last 12 months Jazz Pharmaceuticals's share price moved +31.0% and Johnson & Johnson's +33.2%; against the S&P 500 that is +25.3 points and +27.5 points.
- In their last fiscal years Jazz Pharmaceuticals kept -8.3% of revenue as net income and Johnson & Johnson 28.5%.
- In the last 90 days insiders reported 0 open-market purchases at Jazz Pharmaceuticals and 0 at Johnson & Johnson; members of Congress disclosed 0 trades in Jazz Pharmaceuticals and 5 in Johnson & Johnson.
- Next results: Jazz Pharmaceuticals Feb 22, 2027, Johnson & Johnson Jan 26, 2027.
How each one makes money: Jazz Pharmaceuticals revenue
Share prices on one chart
Jazz Pharmaceuticals and Johnson & Johnson, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Jazz Pharmaceuticals JAZZNASDAQ · Pharmaceuticals | Johnson & Johnson JNJNYSE · Pharmaceuticals | |
|---|---|---|
| Size and profitability | ||
| Market value | $14.8B | $651B |
| Revenue, last fiscal year | $4.27B | $94.2B |
| Net income, last fiscal year | −$356M | $26.8B |
| Net marginNet income as a share of revenue | -8.3% | 28.5% |
| Free cash flow | $1.3B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Johnson & Johnson against
Common questions
How is Jazz Pharmaceuticals different from Johnson & Johnson?
Jazz Pharmaceuticals (JAZZ) is in Pharmaceuticals on NASDAQ, with $4.27B of revenue in its last fiscal year and a net margin of -8.3%. Johnson & Johnson (JNJ) is in Pharmaceuticals on NYSE, with $94.2B of revenue in its last fiscal year and a net margin of 28.5%. The biggest part of Jazz Pharmaceuticals's revenue is Xywav (39%); at Johnson & Johnson it is Innovative Medicine (64%). Jazz Pharmaceuticals earns 90% of its revenue in the United States, Johnson & Johnson 57%. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Jazz Pharmaceuticals and Johnson & Johnson compare in size?
Johnson & Johnson has the larger market value: Jazz Pharmaceuticals $14.8B and Johnson & Johnson $651B, at the last close.
Whose share price rose more over the last 12 months, JAZZ or JNJ?
Over the last 12 months Jazz Pharmaceuticals moved +31.0% and Johnson & Johnson +33.2%. Past price moves say nothing about the future.
Which has had more insider buying, Jazz Pharmaceuticals or Johnson & Johnson?
Since 2006, Jazz Pharmaceuticals insiders reported 73 open-market purchases against 25 for Johnson & Johnson. These are counts of what was filed, not a view on either stock.
Do members of Congress trade JAZZ or JNJ?
In the last 12 months, members of Congress disclosed 0 trades in Jazz Pharmaceuticals (JAZZ) and 24 in Johnson & Johnson (JNJ).
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Jazz Pharmaceuticals pageJohnson & Johnson pageRare insider trades this weekAll comparisons
https://oqro.io/compare/jazz-vs-jnj







